Announcements Trials
Browse Landscape

Phase

Phase 2 15Phase 1/2 3Phase 1 3Phase NA 1Phase 4 1

Status

Completed 2Unknown 1Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

NRG1-fused Non-small Cell Lung Cancer 1

Interventions

Metformin 16Cyclophosphamide 16Drug Therapy 14Dexamethasone 14Cisplatin 13Cytarabine 11Gemcitabine 10Radiotherapy 9Oxaliplatin 9Carboplatin 9Vincristine 8Paclitaxel 8Idarubicin 8Etoposide 8Docetaxel 8ulipristal acetate 7icotinib 7Sodium Chloride 7Methotrexate 7Fluorouracil 7Dexmedetomidine 7entecavir 6Thalidomide 6Surgical Procedures, Operative 6Sorafenib 6Pemetrexed 6Leuprolide 6Granulocyte Colony-Stimulating Factor 6Epirubicin 6Doxorubicin 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 4 × Unknown × Afatinib × Clear all
NCT04814056 2021-04-01

To Evaluate the Efficacy of Afatinib in the Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer With NRG1 Fusion

Shanghai Chest Hospital

Phase 4 Unknown
15 enrolled
Thoracic

NRG1-fused Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡